Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02635009 · ClinicalTrials.gov registry record · Phase 2
Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Limited Stage or Extensive Stage Small Cell Lung Cancer
A Phase 2 study, sponsored by NRG Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 418
- Enrollment target
NCT02635009 is a Phase 2 study that has completed, run by NRG Oncology. The registered enrollment target is 418 participants.
The verdict
NCT02635009, a Phase 2 study, has completed, sponsored by NRG Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 418 participants
- Enrollment target
Study Summary
This randomized phase II/III trial studies how well whole-brain radiation therapy works and compares it with or without hippocampal avoidance in treating patients with small cell lung cancer that is found in one lung, the tissues between the lungs, and nearby lymph nodes only (limited stage) or has spread outside of the lung in which it began or to other parts of the body (extensive stage). Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. The hippocampus is part of the brain that is important for memory. Avoiding the hippocampus during whole-brain radiation could decrease the chance of side effects on memory and thinking. It is not yet known whether giving whole-brain radiation therapy is more effective with or without hippocampal avoidance in treating patients with small cell lung cancer.
Interventions
- RADIATION Intensity-Modulated Radiation Therapy
- RADIATION Three-Dimensional Conformal Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 418 participants |
| Start Date | 2015-12-22 |
| Est. Completion | 2025-09-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02635009
The ClinicalTrials.gov registry entry for NCT02635009 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 418 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NRG Oncology, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Intensity-Modulated Radiation Therapy is the first listed.
NCT02635009 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02635009 about?
NCT02635009 is a clinical study titled "Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Limited Stage or Extensive Stage Small Cell Lung Cancer". This randomized phase II/III trial studies how well whole-brain radiation therapy works and compares it with or without hippocampal avoidance in treating patients with small cell lung cancer that is found in one lung, the tissues between the lungs, and nearby lymph nodes only (limited stage) or has ...
What is the current status of trial NCT02635009?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 418 participants. The study started on 2015-12-22. Estimated completion is 2025-09-04.
What interventions are being tested in trial NCT02635009?
The interventions under investigation include: Intensity-Modulated Radiation Therapy (RADIATION), Three-Dimensional Conformal Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT02635009?
This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.